

CERTIFICATE OF ANALYSIS

Report issued to	NEOLPHARMA Grupo Farmaceutico	Report No.	CMC/LAB/NPTES4/2026
Sample Name	NeolPharma Tesamorelin 10mg GHRH	ULR No.	NA
Manufacturer	NEOLPHARMA Grupo Farmaceutico (Mexico)	Reporting Date	24-01-2026
Active Ingredient	Tesamorelin (GHRH)	Sample Submitted By	Ing. Ricardo Alvarez Mendez, QA Manager (NEOLPHARMA)
Package	10 mg vial	Exp. Date	01/2029
Batch / Lot No.	NPTES4	Sample Qty.	1 vial
Received Date	21-01-2026	Mfg. Lic. No.	COFEPRIS 153300201X0092
Sample Condition	Received in sealed intact condition	Ref. No.	NIL
Storage Condition	Store below 30C away from direct sunlight	Country of Origin	Mexico

Reference to Protocol / Method	USP 2024 . CMC-LAB/SOP/NPTES4	Analysis Started on:	22-01-2026
Analysis Completed on:	23-01-2026	Review / Release Date:	24-01-2026

RESULT OF ANALYSIS


S.No	Test Parameter	Claim	Units	Results	Specifications	Test Method
1	Description	-	-	Complies	White to off-white lyophilized powder.	Visual Evaluation.
2	Identification (HPLC)	-	-	Complies	Positive for Tesamorelin	HPLC
3	Peptide Purity (HPLC)	-	%	98.8	NLT 95.0%	HPLC
4	Assay (Tesamorelin)	10	mg	10.06	9.5 mg to 10.5 mg	HPLC
5	Molecular Weight (LC-MS)	-	-	Complies	Consistent with Tesamorelin (expected MW 1181.40 Da)	LC-MS
6	Water Content (Karl Fischer)	-	%	1.7	NMT 3.0%	KF
7	pH (1% Solution)	-	-	6.22	5.0 to 7.0	USP <791>
8	Sterility	-	-	Complies	No evidence of microbial growth	USP <71>
9	Bacterial Endotoxin	-	EU/mg	< 0.25	NMT 1.0 EU/mg	USP <85>
10	Appearance of Solution	-	-	Complies	Clear, colorless solution	Visual Evaluation.

*The sample submitted by NEOLPHARMA Grupo Farmaceutico **COMPLIES** with the declared specifications and is of standard pharmaceutical quality with respect to the parameters tested.*

USP = United States Pharmacopeia . HPLC = High Performance Liquid Chromatography . KF = Karl Fischer

LC-MS = Liquid Chromatography - Mass Spectrometry . NMT = Not More Than . EU = Endotoxin Units

AV = Acceptance Value . COFEPRIS = Comision Federal para la Proteccion contra Riesgos Sanitarios



QFB. Laura A. Martinez Rios
Chief Analyst, Costamed Laboratory





Dr. Arturo Gonzalez Pena
Technical Director, Costamed Laboratory

**** End of Report ****

Page 1 of 30

Terms and Conditions

1. This report is issued by Costamed Grupo Medico and refers only to the sample tested.
2. Sample will be destroyed one year from the date of issue unless otherwise specified.
3. Total liability of the laboratory is limited to the invoiced amount.
4. All disputes subject to Cozumel, Quintana Roo jurisdiction, Mexico.